We updated the design of this site on September 25th. Learn more.

Carboplatin Plus Vincristine in Treating Children With Retinoblastoma

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00002794

First Posted: April 26, 2004

Last Update Posted: October 4, 2011

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Collaborator:

National Cancer Institute (NCI)

Information provided by:

St. Jude Children's Research Hospital

Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of carboplatin plus vincristine in treating children with retinoblastoma.

Condition	Intervention	Phase
Retinoblastoma	Drug: carboplatin Drug: vincristine sulfate	Phase 2


Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Evaluation of Chemotherapy as Initial Treatment for Retinoblastoma

Resource links provided by NLM:

Genetics Home Reference related topics: retinoblastoma

Drug Information available for: Vincristine sulfate Carboplatin

Genetic and Rare Diseases Information Center resources: Retinoblastoma Neuroepithelioma

U.S. FDA Resources

Further study details as provided by St. Jude Children's Research Hospital:


Enrollment:	25
Study Start Date:	February 1996
Study Completion Date:	June 2001
Primary Completion Date:	June 2001 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES: I. Estimate the objective response rate in infants and children with retinoblastoma when treated with carboplatin (CBDCA) and vincristine (VCR) every 3 weeks for 24 weeks. II. Assess the success of this regimen in delaying radiotherapy and eliminating the need for surgery by estimating the cumulative incidence function of treatment failure. III. Estimate the cumulative incidence of failure of this regimen as measured by subsequent treatment with radiotherapy or surgery.

OUTLINE: All patients receive carboplatin and vincristine every 3 weeks for a maximum of 8 courses. Patients with disease progression after at least 2 courses are removed from study and considered for alternative therapy. Patients are followed every 6 weeks for 1 year, every 2 months for 1 year, every 3-4 months for 3 years, and yearly for 12 years.

PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 4.5 years.

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	up to 10 Years (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS: Newly diagnosed retinoblastoma Bilateral or multifocal unilateral disease in children under age 10 Unilateral, multifocal tumors less than 5 dd in children under age 2 No metastatic disease Disease evidenced by ophthalmoscopic/imaging exam, ultrasound, CT, or MRI Fundus drawings and photographs required

PATIENT CHARACTERISTICS: Age: 10 and under Performance status: Not specified Life Expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery: Not specified

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002794

Locations


United States, Tennessee
University of Tennessee, Memphis Cancer Center
Memphis, Tennessee, United States, 38103
Saint Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105-2794

Sponsors and Collaborators

St. Jude Children's Research Hospital

National Cancer Institute (NCI)

Investigators


Study Chair:	Carlos Rodriguez-Galindo, MD	St. Jude Children's Research Hospital

More Information

Additional Information:

St. Jude Children's Research Hospital This link exits the ClinicalTrials.gov site


ClinicalTrials.gov Identifier:	NCT00002794 History of Changes
Other Study ID Numbers:	CDR0000064874 P30CA021765 ( U.S. NIH Grant/Contract ) P01CA023099 ( U.S. NIH Grant/Contract ) SJCRH: RET3 NCI-H96-0935
First Submitted:	November 1, 1999
First Posted:	April 26, 2004
Last Update Posted:	October 4, 2011
Last Verified:	October 2011

Keywords provided by St. Jude Children's Research Hospital:


intraocular retinoblastoma

Additional relevant MeSH terms:


Retinoblastoma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Retinal Neoplasms Eye Neoplasms Neoplasms by Site	Eye Diseases Retinal Diseases Carboplatin Vincristine Antineoplastic Agents Antineoplastic Agents, Phytogenic Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action

To Top